Quantitative determination of pravastatin and R-416, its main metabolite in human plasma, by liquid chromatography–tandem mass spectrometry

Kawabata, Kiyoshi; Samata, Naozumi; Urasaki, Yoko

doi:10.1016/j.jchromb.2004.11.014

Cited by 28 publications

(27 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Plasma and urine samples were collected on day 5 (for olmesartan single-dose pharmacokinetics) and on day 8 (for the pharmacokinetic interaction study) in the same manner as on day 1. The concentrations of all test compounds in plasma and urine were determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS) as described in earlier reports (Kawabata et al 2005;Nishizato et al 2003).…”

Section: Subjects and Genotyping Of Slco1b1mentioning

confidence: 99%

Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism

et al. 2008

Self Cite

View full text Add to dashboard Cite

The impact of SLCO1B1 polymorphism on the pharmacokinetics of olmesartan and on the pharmacokinetic interaction between pravastatin and olmesartan was investigated. On day 1, ten healthy volunteers took an oral dose (10 mg) of pravastatin. After a 3-day washout period, each subject received olmesartan medoxomil (10 mg) for 3 days. On day 8, they received olmesartan medoxomil (10 mg) and pravastatin (10 mg) concurrently, and pharmacokinetic profiles were compared with those in each single-dose phase with regard to the SLCO1B1 genotypes (*1b/*1b, *1b/*15, and *15/*15). In the single-dose phase, the mean C max and AUC 0-24 of olmesartan tended to be higher in *15/*15 subjects than in *1b/*1b subjects, while the mean CL t /F (±SD) in *15/*15 subjects was significantly lower than that in *1b/*1b subjects. No statistically significant differences were observed in any pharmacokinetic parameters between single-dose and co-administration phases for both pravastatin and RMS-416. These results suggest that OATP1B1 plays a role in the pharmacokinetics of olmesartan, and the co-administration of olmesartan does not affect the pharmacokinetics of pravastatin or its metabolite, RMS-416, although larger scale clinical studies are needed to confirm these observations due to the small sample size in the present study.

show abstract

Section: Subjects and Genotyping Of Slco1b1mentioning

confidence: 99%

Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism

et al. 2008

Self Cite

View full text Add to dashboard Cite

show abstract

“…In previous studies, for analysis of pitavastatin, liquidliquid extraction (Chung et al, 2005;Kojima et al, 1999) or column switching (Kojima et al, 1999) methods have been used for cleaning up pitavastatin in plasma samples, whereas a solid-phase extraction method has been reported for cleaning of pravastatin (Kawabata et al, 2005;Zhu and Neirinck, 2003;Miao and Metcalfe, 2003;Mulvana et al, 2000). We found that pitavastatin could be also purified by solid-phase extraction method, and that this was much simpler than the pretreatment procedure used previously (Chung et al, 2005;Kojima et al, 1999).…”

Section: Pharmacokinetics Of Pravastatin and Pitavastatinmentioning

confidence: 71%

“…Therefore, pravastatin and pitavastatin may be used as useful probe substrates for study of OATP1B1 genetic polymorphism and OATP1B1-related drug-drug interaction. Several methods have been described for the analysis of either pravastatin alone (Kawabata et al, 2005;Zhu and Neirinck, 2003), or pravastatin with other statins such as atorvastatin, lovastatin, simvastatin and rosuvastatin (Pasha et al, 2006;Miao and Metcalfe, 2003) in plasma using LC-MS/MS employing solidphase extraction. However, the previously published HPLC methods for quantitation of pitavastatin require a large volume (1.0 mL) of plasma and a tedious liquidliquid extraction step (Chung et al, 2005;Kojima et al, 1999).…”

Section: Introductionmentioning

confidence: 99%

Determination of two HMG‐CoA reductase inhibitors, pravastatin and pitavastatin, in plasma samples using liquid chromatography–tandem mass spectrometry for pharmaceutical study

Deng

Kim

Song

et al. 2007

Biomedical Chromatography

View full text Add to dashboard Cite

We developed a method for determining pravastatin or pitavastatin, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, in plasma using liquid chromatography and tandem mass spectrometry (LC-MS/MS). Pravastatin, pitavastatin and the internal standard fluvastatin were extracted from plasma with solid-phase extraction columns and eluted with methanol. After drying the organic layer, the residue was reconstituted in mobile phase (acetonitrile:water, 90:10, v/v) and injected onto a reversed-phase C(18) column. The isocratic mobile phase was eluted at 0.2 mL/min. The ion transitions recorded in multiple reaction monitoring mode were m/z 423 --> 101, 420 --> 290 and 410 --> 348 for pravastatin, pitavastatin and fluvastatin, respectively. The coefficient of variation of the assay precision was less than 12.4%, the accuracy exceeded 89%. The limit of detection was 1 ng/mL for all analytes. This method was used to measure the plasma concentration of pitavastatin or pravastatin from healthy subjects after a single 4 mg oral dose of pitavastatin or 40 mg oral dose of pravastatin. This is a very simple, sensitive and accurate analytic method to determine the pharmacokinetic profiles of pitavastatin or pravastatiny.

show abstract

“…Literature survey reveals that pravastatin is official in British Pharmacopoeia (British Pharmacopoeia, 2007a). Several analytical methods are available for the estimation of pravastatin in bulk, pharmaceutical dosage forms and biological matrices, these include UV spectrophotometry (Balaji and Suman, 2009;Kunjan et al, 2014), visible spectrophotometry (Kalvikkarasi et al, 2009;Safwan and Mouhammed, 2011), HPLC (Bauer et al, 2005;Önal and Sagirli, 2006;Brain-Isasi et al, 2008;Safwan et al, 2008;Raj et al, 2010;Jane and Janivishal, 2013;Vania, 2014), LC-MS (Mulvana et al, 2000;Zhu and Neirinck, 2003;Kawabata et al, 2005;Sampath et al, 2011), capillary electrophoresis (Kircali et al, 2004;Nigovic and Vegar, 2008) and voltammetry (Nigović, 2006). Aspirin, chemically known as 2-acetyloxybenzoic acid (Figure 2), is a nonsteroidal anti-inflammatory drug used in the temporary relief of various forms of pain and inflammation associated with various conditions (Valentin and Joseph, 2011).…”

Section: Pravastatin Chemically Known As (3r5r)-7-[(1s2s6s8s8armentioning

confidence: 99%

Stability Indicating HPLC Method for the Simultaneous Quantification of Aspirin and Pravastatin in bulk and Tablets: Method Development and Validation

2017

J App Pharma Sci

View full text Add to dashboard Cite

The aim of the present study was to develop and validate a stability indicating HPLC method for the simultaneous determination of aspirin and pravastatin in bulk and pharmaceutical dosage forms. The chromatographic separation of aspirin, pravastatin and their degradation products was achieved on Phenomex C18 column with mixture of water, acetonitrile and acetic acid (40:59:01, v/v/v) as mobile phase in an isocratic elution mode at a flow rate of 1.5 mL/min. The method exhibited linearity in the concentration range of 20.5 -61.5 μg/mL and 10-30 μg/mL for aspirin and pravastatin, respectively. The limits of detection and quantification were 0.204μg/mL and 0.680 μg/mL for aspirin and 0.077 μg/mL and 0.256 μg/mL for pravastatin, respectively. The developed method was validated with respect to accuracy, precision, selectivity, specificity and robustness. All the parameters examined were within the acceptance limits. The stability-indicating power of the proposed method was proved by subjecting the drugs to hydrolytic (acid and base), oxidative, photolytic and dry heat stress conditions. The developed method was found to be suitable for routine analysis of aspirin and pravastatin simultaneous in the presence of its stress degradation products.

show abstract

Quantitative determination of pravastatin and R-416, its main metabolite in human plasma, by liquid chromatography–tandem mass spectrometry

Cited by 28 publications

References 14 publications

Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism

Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism

Determination of two HMG‐CoA reductase inhibitors, pravastatin and pitavastatin, in plasma samples using liquid chromatography–tandem mass spectrometry for pharmaceutical study

Stability Indicating HPLC Method for the Simultaneous Quantification of Aspirin and Pravastatin in bulk and Tablets: Method Development and Validation

Contact Info

Product

Resources

About